Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic GU business drops Vision-Sciences' urology products:

This article was originally published in Clinica

Executive Summary

Vision-Sciences, the Natick, Massachusetts developer of flexible endoscopes, is to sell its urology products directly to customers in the US and Canada after its distribution agreement with Medtronic Gastroenterology/Urology (MGU) was terminated. MGU said it was reducing the number of uro-diagnostics products it was offering - including Vision Sciences' flexible cystoscope and slide-on Endosheath system - as it wanted to focus more on treatment products. To ensure a smooth transition of sales and services to customers, MGU will continue to take orders from the existing base and provide technical support up to November. The termination of this agreement does not affect another distribution arrangement between the two companies concerning Vision-Sciences' ENT products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel